Insmed continues to expect cash-based operating expenses to be in the range of $150M-$170M for the first half of 2019. In addition, the Company expects capital expenditures, including spend related to the buildout of a new corporate headquarters facility as well as payments classified within other assets for the future right-of-use asset related to the buildout of an additional third-party manufacturing facility, to be in the range of $25M-$35M for the first half of 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.